Healthcare Nov 29, 2021 02:14 PM (GMT+8)
On November 29, Yuanyin (Beijing) Biotechnology Co., Ltd. announced that it had completed the pre-A round of financing of more than 100 million yuan, which was led by quanchuang capital and followed by Qianji capital. Yuanyin biology was founded by Professor Wei Wensheng of Peking University in April 2021. The company focuses on developing vaccines and new treatments by using circular RNA technology. This round of financing will be mainly used for preclinical and clinical research of new drug pipeline.
The Wei Wensheng laboratory is the world's first research group to apply circular RNA technology to vaccine research and development. In early 2021, it reported the results of a circular RNA vaccine against COVID-19 and its variants. Professor Wei Wensheng said: "the application and transformation of circular RNA technology in the new crown vaccine provides the possibility for the application of a series of diseases in the future. We also pay attention to the expression of therapeutic proteins or peptides to benefit the treatment of rare diseases and cancer."
Dr. Xu Xiaoxing of quanchuang capital said: "as an emerging technology platform, circular RNA can be applied and extended to multiple treatment fields, and is expected to provide patients with more effective and convenient drugs.
Dr. Wu Hai of Qianji capital said: "circular RNA can regulate the expression of various proteins at the mRNA level, and its characteristics such as high stability, long protein expression duration and simple production process will provide a new solution for the target of clinical unprocessed drugs. We are optimistic about the rapid transformation ability and strong ductility based on the independent intellectual property technology platform."
This text is a result of machine translation.